Puma Biotechnology Inc. buy WatchMen
Start price
26.03.24
/
50%
€5.30
Target price
26.03.25
€10.00
Performance (%)
-30.72%
End price
16.07.24
€3.67
Summary
This prediction ended on 16.07.24 with a price of €3.67. Massive losses of -30.72% were the result for the BUY prediction by WatchMen. WatchMen has a follow-up prediction for Puma Biotechnology Inc. where he still thinks Puma Biotechnology Inc. is a Buy. WatchMen has 50% into this predictionPuma Biotechnology is a publicly traded biopharmaceutical company that develops innovative cancer therapies targeting the most aggressive and difficult-to-treat forms of the disease. Puma's lead product is Nerlynx, an oral medication approved for the treatment of HER2-positive breast cancer, and the company also has a number of other promising drugs in its pipeline. Founded in 2010, Puma is headquartered in Los Angeles, California, and its shares trade on the NASDAQ exchange under the ticker symbol PBYI.
Performance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Puma Biotechnology Inc. | -2.598% | -2.598% |
| iShares Core DAX® | 1.280% | 1.027% |
| iShares Nasdaq 100 | -2.457% | -4.650% |
| iShares Nikkei 225® | -2.006% | -2.091% |
| iShares S&P 500 | -0.662% | -1.246% |
Comments by WatchMen for this prediction
In the thread Puma Biotechnology Inc. diskutieren
Buy Puma Biotechnology Inc.